What are the uses and dosing guidelines for cephalexin in treating bacterial infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 31, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cephalexin Uses and Dosing Guidelines

Cephalexin is a first-generation oral cephalosporin antibiotic primarily used to treat skin and soft tissue infections, respiratory tract infections, urinary tract infections, and bone infections caused by methicillin-susceptible Staphylococcus aureus (MSSA) and Streptococcus species. 1

Primary Clinical Indications

Skin and Soft Tissue Infections

  • The standard adult dose is 500 mg orally every 6 hours (four times daily) for MSSA skin infections, as recommended by the Infectious Diseases Society of America 2, 3
  • For surgical site infections following clean procedures (trunk or extremity surgery away from axilla/perineum), cephalexin 500 mg every 6 hours orally is an appropriate option 2
  • Cephalexin achieves cure rates of 90% or higher for streptococcal and staphylococcal skin infections 4
  • Treatment duration is typically 7-10 days depending on clinical response 3, 5

Respiratory Tract Infections

  • For streptococcal pharyngitis and tonsillitis, cephalexin is comparable to penicillin in efficacy 6
  • Adult dosing: 500 mg every 12 hours for streptococcal pharyngitis 1
  • Critical limitation: Cephalexin has poor activity against Haemophilus influenzae, making it inappropriate for sinusitis, many community-acquired pneumonias, and otitis media where H. influenzae is suspected 7, 6, 3
  • For beta-hemolytic streptococcal infections, treatment must continue for at least 10 days to prevent rheumatic fever 1, 3

Urinary Tract Infections

  • For uncomplicated cystitis in patients over 15 years: 500 mg every 12 hours for 7-14 days 1
  • Cephalexin achieves urinary concentrations of 500-1000 mcg/mL following 250-500 mg oral doses, far exceeding minimum inhibitory concentrations for common uropathogens 8
  • Single-dose therapy (3 g) shows 67% cure rates for acute uncomplicated UTIs, though this is not standard practice 9

Dosing by Patient Population

Adult Dosing

  • Standard range: 1-4 grams daily in divided doses 1
  • Usual dose: 250 mg every 6 hours for mild infections 1
  • For moderate-to-severe infections: 500 mg every 6 hours 1, 3
  • If doses exceeding 4 grams daily are required, switch to parenteral cephalosporins (e.g., cefazolin 1 g IV every 8 hours) 10

Pediatric Dosing

  • Standard: 25-50 mg/kg/day divided into 4 doses for mild-to-moderate infections 1, 3
  • For MSSA infections: 75-100 mg/kg/day divided into 3-4 doses 3, 10
  • For otitis media: 75-100 mg/kg/day in 4 divided doses is required 1
  • For streptococcal pharyngitis and skin infections in children over 1 year, the total daily dose may be divided every 12 hours 1

Renal Impairment

  • Patients with creatinine clearance <30 mL/min require dose reduction proportional to reduced renal function 8

Antimicrobial Spectrum and Critical Limitations

Effective Coverage

  • Methicillin-susceptible Staphylococcus aureus (MSSA) 3, 10, 4
  • Streptococcus pyogenes (Group A Streptococcus) 6, 4
  • Other beta-hemolytic streptococci 1, 6

Critical Coverage Gaps (Common Pitfalls)

  • Completely ineffective against MRSA - if MRSA is suspected, use trimethoprim-sulfamethoxazole, doxycycline, or clindamycin instead 10, 5, 3
  • Poor activity against Haemophilus influenzae - do not use for sinusitis, otitis media, or respiratory infections where H. influenzae is likely 7, 6, 3
  • Inadequate against Moraxella catarrhalis (beta-lactamase producing strains) 3
  • No activity against Pseudomonas aeruginosa 3
  • Limited anaerobic coverage - unsuitable for deep abscesses or infections requiring anaerobic coverage 10
  • Poor coverage for Pasteurella multocida (animal bites) and Eikenella corrodens (human bites) 10
  • High resistance rates (96%) among viridans group streptococci - not recommended for endocarditis prophylaxis 3

Special Clinical Considerations

Penicillin Allergy

  • Cephalexin can be used in patients with non-severe penicillin allergy (non-IgE mediated reactions) 10, 5
  • Contraindicated in patients with history of anaphylaxis, angioedema, or urticaria to penicillins due to potential cross-reactivity 3, 5

Pregnancy and Lactation

  • For lactating women with mastitis: 500 mg orally every 6 hours 3
  • Cephalexin achieves therapeutic levels in breast milk (0.09-0.59 mcg/mL in healthy milk; 0.57-1.05 mcg/mL in infected milk) and is considered safe for nursing infants 3

Administration and Storage

  • Cephalexin is absorbed in the upper intestine, not the stomach, ensuring reliable bioavailability 8
  • Does not disturb lower bowel flora due to absorption high in the intestinal tract 8
  • Suspension must be refrigerated after mixing and remains stable for 14 days 1

Algorithm for Appropriate Use

Step 1: Identify the infection type and likely pathogens

  • Skin/soft tissue with suspected MSSA/Streptococcus → Cephalexin appropriate
  • Respiratory infection with possible H. influenzae → Choose alternative agent
  • Suspected MRSA → Choose alternative agent (TMP-SMX, doxycycline, clindamycin)

Step 2: Assess patient factors

  • Penicillin allergy history: severe (anaphylaxis/angioedema) → avoid cephalexin; non-severe → cephalexin acceptable
  • Renal function: CrCl <30 mL/min → reduce dose proportionally

Step 3: Select appropriate dose

  • Adults: 500 mg every 6 hours for most infections
  • Children: 25-50 mg/kg/day (mild) or 75-100 mg/kg/day (MSSA) in divided doses
  • Duration: 7-10 days (minimum 10 days for streptococcal infections)

Step 4: Monitor for treatment failure

  • If no improvement by day 5, consider MRSA, resistant organisms, or alternative diagnosis 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Cephalexin Dosing Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Cephalexin Dosing for Skin Abrasion

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Cephalexin in lower respiratory tract infections.

Postgraduate medical journal, 1983

Research

The pharmacology of cephalexin.

Postgraduate medical journal, 1983

Guideline

Cephalexin Dosing for Soft Tissue Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.